- Home
- SCNI vs LIXT Comparison
SCNI vs LIXT Comparison
Compare SCNI & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- LIXT
- Stock Information
- Founded
- SCNI 2003
- LIXT 2005
- Country
- SCNI Israel
- LIXT United States
- Employees
- SCNI N/A
- LIXT N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- SCNI Health Care
- LIXT Health Care
- Exchange
- SCNI Nasdaq
- LIXT Nasdaq
- Market Cap
- SCNI 2.3M
- LIXT 2.2M
- IPO Year
- SCNI N/A
- LIXT N/A
- Fundamental
- Price
- SCNI $2.24
- LIXT $4.00
- Analyst Decision
- SCNI
- LIXT
- Analyst Count
- SCNI 0
- LIXT 0
- Target Price
- SCNI N/A
- LIXT N/A
- AVG Volume (30 Days)
- SCNI 93.4K
- LIXT 6.2M
- Earning Date
- SCNI 08-14-2025
- LIXT 08-07-2025
- Dividend Yield
- SCNI N/A
- LIXT N/A
- EPS Growth
- SCNI N/A
- LIXT N/A
- EPS
- SCNI N/A
- LIXT N/A
- Revenue
- SCNI $658,000.00
- LIXT N/A
- Revenue This Year
- SCNI N/A
- LIXT N/A
- Revenue Next Year
- SCNI N/A
- LIXT N/A
- P/E Ratio
- SCNI N/A
- LIXT N/A
- Revenue Growth
- SCNI N/A
- LIXT N/A
- 52 Week Low
- SCNI $1.90
- LIXT $0.64
- 52 Week High
- SCNI $8.92
- LIXT $4.45
- Technical
- Relative Strength Index (RSI)
- SCNI 46.99
- LIXT 80.89
- Support Level
- SCNI $2.06
- LIXT $2.02
- Resistance Level
- SCNI $2.85
- LIXT $4.25
- Average True Range (ATR)
- SCNI 0.23
- LIXT 0.54
- MACD
- SCNI 0.01
- LIXT 0.30
- Stochastic Oscillator
- SCNI 30.38
- LIXT 96.99
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.